ANIX Narrows Losses but Revenue Still Zero

Anixa Biosciences (ANIX) reported its fiscal 2026 Q1 earnings on March 9, 2026, with total revenue remaining stable at $0, consistent with the prior year. The company reduced its net loss to $-2.58 million, a 19.5% improvement from $-3.21 million in 2025 Q1, while earnings per share improved by 20.0% to -$0.08 from -$0.10. No guidance adjustments were explicitly provided in the report.

Revenue

The total revenue of Anixa Biosciences remained stable at $0 in 2026 Q1 with no significant change from 2025 Q1.

Earnings/Net Income

Anixa Biosciences narrowed losses to $0.08 per share in 2026 Q1 from a loss of $0.10 per share in 2025 Q1 (20.0% improvement). Meanwhile, the company successfully narrowed its net loss to $-2.58 million in 2026 Q1, reducing losses by 19.5% compared to the $-3.21 million net loss reported in 2025 Q1. The reduced loss per share indicates progress in managing operational costs despite ongoing revenue challenges.

Price Action

The stock price of Anixa Biosciences has climbed 3.47% during the latest trading day, has edged up 0.68% during the most recent full trading week, and has edged up 2.05% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Anixa Biosciences (ANIX) shares 30 days after the release of a quarterly financial report with revenue equal to or greater than the previous quarter has delivered strong returns over the past three years. The strategy achieved an overall return of 82.15%, surpassing the benchmark return of 57.87% and generating an excess return of 24.28%. The strategy's CAGR was 16.31%, indicating steady growth, while the Sharpe ratio of 0.29 suggests a reasonable risk-adjusted return. The maximum drawdown was 69.72%, reflecting a moderate level of risk. However, the high volatility of 55.43% indicates significant price fluctuations.

Additional News

Anixa Biosciences recently secured a Korean patent allowance for its breast cancer vaccine platform, expanding its intellectual property portfolio in South Korea and supporting future commercialization efforts. The patent, titled "Vaccine Adjuvants and Formulations," complements existing U.S. protections. Separately, the stock fell 1.75% pre-market to $2.8 after phase 1 trial data for its breast cancer vaccine failed to meet expectations. The company also disclosed R&D expenses of $1.615 million and operating losses of $3.051 million in its latest financial report.

(text2img/)